Likely yes for many patients
Only you can determine what fits your situation
Thus, in perfect agreement with the recent ADA-EASD consensus report [6], we also encourage the adoption of GLP-1RA plus SGLT2i combination therapy in T2DM patients with established ASCVD (coronary artery disease, cerebrovascular disease, or peripheral arterial disease) or multiple risk factors for ASCVD (i.e., age 55 years, obesity, dyslipidemia, hypertension, current tobacco use, left ventricular hypertrophy, and/or proteinuria) whose HbA1c remains suboptimal despite initial treatment with only one of these agents
Calanna S, Christensen M, Holst JJ, Laferrre B, Gluud LL, Vilsbll T, et al
Semaglutide , a GLP-1 receptor agonist, is an effective medication for both type 2 diabetes and weight management, and our medical team will be with you every step of the way
Use GoodRx only if manufacturer programs are unavailable